NASDAQ:FDMT

4d Molecular Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy FDMT

*Your capital is at risk

$9.53

+0.260 (+2.80%)

At Close: Jun 03, 2026

4D Molecular Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 94.68. In total, the insiders bought 29.81M and sold 12.45M FDMT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	94.68
● Buy	29.81M shares
● Sell	12.45M shares
77% Buy Activity Moderate Negative Correlation
Buy Signal High Confidence Mar 25, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 94.68. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (77% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Tomasello Shawn Director	Director	22 500 Value: $93.4K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Theuer Charles Director	Director	22 500 Value: $93.4K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Miller-rich Nancy Director	Director	22 500 Value: $93.4K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Milligan John F Director	Director	33 750 Value: $140.1K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Milligan John F Director	Director	33 750 Value: $140.1K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Miller-rich Nancy Director	Director	22 500 Value: $93.4K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Theuer Charles Director	Director	22 500 Value: $93.4K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Tomasello Shawn Director	Director	22 500 Value: $93.4K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Gray Susannah Director	Director	22 500 Value: $93.4K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Chacko Jacob Director	Director	22 500 Value: $93.4K
Mar 06, 2025 Buy	Stock Option (Right to Buy) A-Award	Bizily Scott Chief Legal Officer	Officer	78 500 Value: $325.0K
Mar 06, 2025 Buy	Stock Option (Right to Buy) A-Award	Kirn David Chief Executive Officer	CEO / President	267 500 Value: $1.11M
Mar 06, 2025 Buy	Stock Option (Right to Buy) A-Award	Kim Robert Young Chief Medical Officer	Officer	92 300 Value: $382.1K
Mar 06, 2025 Buy	Stock Option (Right to Buy) A-Award	Mehra Uneek See Remarks	Officer	130 000 Value: $538.2K
Mar 06, 2025 Buy	Stock Option (Right to Buy) A-Award	Kamal Fariborz President & COO	CEO / President	178 400 Value: $738.6K
Mar 06, 2025 Buy	Stock Option (Right to Buy) A-Award	Kamal Fariborz President & COO	CEO / President	178 400 Value: $738.6K
Mar 06, 2025 Buy	Stock Option (Right to Buy) A-Award	Mehra Uneek See Remarks	Officer	130 000 Value: $538.2K
Mar 06, 2025 Buy	Stock Option (Right to Buy) A-Award	Kim Robert Young Chief Medical Officer	Officer	92 300 Value: $382.1K
Mar 06, 2025 Buy	Stock Option (Right to Buy) A-Award	Kirn David Chief Executive Officer	CEO / President	267 500 Value: $1.11M
Mar 06, 2025 Buy	Stock Option (Right to Buy) A-Award	Bizily Scott Chief Legal Officer	Officer	78 500 Value: $325.0K
Dec 09, 2024 Sell	Common Stock J-Other	Ra Capital Management, L.p. 10 Percent Owner	10% Owner	535 000 Value: $0
Dec 09, 2024 Buy	Pre-Funded Warrants (Right to Buy) J-Other	Ra Capital Management, L.p. 10 Percent Owner	10% Owner	535 000 Value: $54
Dec 09, 2024 Buy	Pre-Funded Warrants (Right to Buy) J-Other	Ra Capital Management, L.p. 10 Percent Owner	10% Owner	535 000 Value: $54
Dec 09, 2024 Sell	Common Stock J-Other	Ra Capital Management, L.p. 10 Percent Owner	10% Owner	535 000 Value: $0
Nov 13, 2024 Buy	Common Stock	Ra Capital Management, L.p. 10 Percent Owner	10% Owner	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT 4D MOLECULAR THERAPEUTICS, INC.

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; ...

Read Full Profile Here